Home » Stocks » Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc. (PHAT)

Stock Price: $31.58 USD -0.62 (-1.93%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 914.70M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 28.96M
EPS (ttm) -23.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $31.58
Previous Close $32.20
Change ($) -0.62
Change (%) -1.93%
Day's Open 32.88
Day's Range 30.42 - 32.88
Day's Volume 103,686
52-Week Range 18.51 - 64.54

More Stats

Market Cap 914.70M
Enterprise Value 704.69M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 28.96M
Float 7.23M
EPS (basic) n/a
EPS (diluted) -23.02
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.02M
Short Ratio 11.12
Short % of Float 6.67%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.97
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 210.01M
Net Cash / Share 7.25
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -16.65%
ROE -264.23%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

(23.50% upside)
Current: 31.58
Target: 39.00
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-106-1.23
Net Income-255-1.29
Shares Outstanding11.376.05
Earnings Per Share-22.45-0.21
Operating Cash Flow-36.51-1.02
Capital Expenditures-0.13-
Free Cash Flow-36.64-1.02
Cash & Equivalents2440.88
Total Debt23.571.95
Net Cash / Debt220-1.07
Book Value228-1.29
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Phathom Pharmaceuticals, Inc.
Country United States
Employees 25
CEO Terrie Curran

Stock Information

Ticker Symbol PHAT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PHAT


Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.